Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Eric R. Fearon · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2020 · $390,000 — Coronaviruses employ two key host proteins to gain entry and replicate within cells, angiotensinconverting enzyme 2 (ACE2), an essential receptor of entry, and cell surface transmembrane protease serine 2 (TMPRSS2), a serine protease that cleaves coronavirus spike proteins following receptor binding…
Mary Szatkowski Ozers · PROTEOVISTA, LLC · 2020 · $129,050 — This application is being submitted as an Administrative Supplement in response to the Notice of Special Interest (NOSI) identified as NOT-CA-20-042. Study of highly infectious diseases, especially those caused by viruses, poses unique biosafety challenges to the scientific research community. Rathe…
Kimberly Frances Raab-Graham · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2020 · $335,999 — PROJECT SUMMARY Overview: The project focuses on understanding the molecular basis of how disrupted calcium homeostasis leads to disrupted hippocampal network activity that results in maladaptive responses in neurons with TSC deficient signaling. Approximately 33% of children who have autism spectru…
Fang Li · UNIVERSITY OF MINNESOTA · 2020 · $455,796 — Receptor recognition and cell entry by viruses are two initial and essential steps in viral infection cycles. They are important determinants of viral host ranges, tissue tropisms and pathogenesis, and are primary targets for human intervention. Coronaviruses (CoVs) pose serious health threats to hu…
RICK B MEEKER · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $388,750 — HIV infection of the nervous system results in chronic infection, inflammation and cognitive decline in many patients with no effective treatments. Inflammation appears early in the disease process and causes progressive neural damage due, in part, to factors released by activated microglia and macr…
Susan Daniel · CORNELL UNIVERSITY · 2020 · $532,013 — Project Summary / Abstract Enveloped viruses access their host cells by binding to receptors on the plasma membrane and then undergoing fusion with the host membrane. Both binding and fusion are mediated by a specific viral “spike” protein that is typically primed for fusion activation by proteolyti…
Michael R. Farzan · SCRIPPS FLORIDA · 2020 · $343,458 — SARS-CoV-2 (2019-nCoV) is a human pathogenic coronavirus that is very similar to the SARS coronavirus (SARS-CoV or SARS-CoV-1). As of this writing, more than 40,000 people are reported to be infected with this virus, causing more than 1,000 deaths. It is hoped that the number of new cases will decli…
Kenneth C Bagley · ORLANCE, INC. · 2020 · $908,934 — ABSTRACT In response to the emerging COVID-19 (SARS-CoV-2) pandemic, this supplement proposal to R44 AI138733- 01 will leverage our cutting-edge nucleic acid vaccine strategies, some of which that were developed under this parent grant. Here, we request supplement funding to develop candidate COVID-…
Henry M. Colecraft · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2020 · $337,499 — Summary This proposal is for a COVID-19-related Administrative Supplement for RO1HL142111, “Ubiquitin regulation of K Channels in Health and Disease”. We propose to adapt/apply tools and approaches including, nanobody development and optical assays of membrane proteins, that we have developed for st…
Daniel K Sodickson · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2020 · $772,877 — PROJECT SUMMARY Competitive Revision to P41 EB017183 The Center for Advanced Imaging Innovation and Research (CAI2R) pursues a mission of bringing people together to create new ways of seeing. The work of our Center has been focused on creating new paradigms for the acquisition, reconstruction, and…
Margaret Juliana McElrath · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $6,554,653 — This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the first COVID-19 vaccine efficacy trial “A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the …
SUSAN H ESHLEMAN · JOHNS HOPKINS UNIVERSITY · 2020 · $167,145 — PROJECT SUMMARY This project will provide laboratory support for a large, cross-sectional COVID-19 seroprevalence study that will be conducted in 23-25 communities in the United States: the SARS-CoV-2 Seroprevalence Study (COVID-19 Prevention Trials Network [CoVPN] 5002). The CoVPN 5002 study will i…
Priyamvada Acharya · DUKE UNIVERSITY · 2020 · $732,990 — Targeting early metastable intermediates of the SARS-CoV-2 spike for vaccine and therapeutics development The ongoing global pandemic of the novel SARS-CoV-2 presents an urgent need for development of effective preventative and treatment therapies. The viral-host cell fusion (S) protein spike is a p…
Xi Chen · UNIVERSITY OF CALIFORNIA AT DAVIS · 2020 · $195,234 — Project Summary Exploring the biology of O-acetyl sialic acids using stable synthetic mimics This supplement request explores the possibility that sialoglycans may be co-receptors for SARS and COVID- 19 virus spike (S) proteins, as is the case with MERS and other Coronaviruses (CoVs). Numerous virus…
Susan Daniel · CORNELL UNIVERSITY · 2020 · $87,264 — Project Summary / Abstract Enveloped viruses access their host cells by binding to receptors on the plasma membrane and then undergoing fusion with the host membrane. Both binding and fusion are mediated by a specific viral “spike” protein that is typically primed for fusion activation by proteolyti…
James R. Heath · INSTITUTE FOR SYSTEMS BIOLOGY · 2020 · $183,000 — Project Summary The pandemic COVID-19 has, as of April 13, 2020, infected nearly 2M individuals worldwide, with over 560,000 U.S. cases and over 22,000 U.S. deaths. There are no FDA approved vaccines or treatments for COVID-19. This supplemental proposal describes the accelerated development of such…
Eva Harris · UNIVERSITY OF CALIFORNIA BERKELEY · 2020 · $241,096 — Supplement to R21: Mechanism and in vivo activity of novel glycan-based therapy against flavivirus endothelial permeability and vascular leak Evaluation of therapeutics targeting SARS-CoV-2 infection and defining pathogenic mechanisms of SARS-CoV-2-triggered pulmonary dysfunction Abstract The emergi…
Philip Daniel Compton · INTEGRATED PROTEIN TECHNOLOGIES, INC. · 2020 · $318,151 — Abstract: The rise of the global SARS-CoV-2 pandemic has exposed serious weaknesses in our ability to respond to novel pathogens. Three major areas of improvement include the rapid development of vaccines, therapeutics, and serosurveillence. All three of these areas require tools that accurately ass…
Michael-Christopher Keogh · EPICYPHER, INC. · 2020 · $396,808 — PROJECT SUMMARY Alterations in histone post-translational modifications (PTMs) are associated with diverse human pathologies. The ability to quantitatively assess these PTMs in healthy and diseased cells is essential to accelerate the development of drugs or diagnostics targeting epigenetic regulat…
Helen E Scharfman · NATHAN S. KLINE INSTITUTE FOR PSYCH RES · 2020 · $404,250 — ABSTRACT It has been suggested that neuronal hyperexcitability is an important characteristic in Alzheimer’s disease (AD) because it contributes to the impairment in memory and increasing levels of amyloid β (Aβ) that characterize the disease. Using animal models of AD neuropathology we suggest tha…